Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Effects of Individualized Training to Reduce Fatigue in Patients With Newly and Advanced Diagnosed Multiple Sclerosis

NCT06201026 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2023-09-12
Last updated
2024-10-23

Condition(s) studied

SclerosisFatigue

Investigational drug(s) / intervention(s)

Traditional exerciseIndividualized exercise

Traditional exercise: Patients will perform aerobic and resistance exercises that are consistent with the exercise guidelines for MS patients at home

Individualized exercise: Patients will performed a mobile-app guided program at home designed to address identified individual disabilities such as loss of muscle strength or cardiorespiratory deconditioning.

Study summary

Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system. It is characterized by complex and heterogeneous symptoms. Chronic fatigue is the most reported symptom in MS patients (80%). Current pharmacological treatments for MS patients reduce the number of relapses and their severity but do not improve symptoms such as fatigue. Physical activity is a therapy that helps reduce this fatigue, in addition to improving muscular and cardiorespiratory functions. However, the results are not optimal because MS patients remain less active than the general population. The improvement of the benefits of exercise therapy could therefore be based on three approaches: personalization of the training program, home practice and early initiation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion criteria * Relapsing-remitting MS (RRMS) defined according to the criteria of McDonald * MS diagnosed less than 2 years ago or whose first symptoms are estimated to be less than 5 years old OR MS diagnosed more than 2 years ago and whose first symptoms are estimated to be less than 5 years old * With a high level of fatigue, corresponding to an FSS score \> 4 * Expanded Disability Status Scale (EDSS) score \< 4 * Medical Research Council (MRC) testing ≥ 4 in all leg muscles * Ability to walk for 10 minutes without stopping (self-reported) * Have a mobile phone with internet access * Affiliated with or benefiting from a social security scheme * Have freely given their written consent after being informed of the aim, the procedure and the potential risks involved Exclusion criteria * Spasticity or severe cerebellar ataxia in either leg. * Abnormal range of movement of the toes and/or ankle * Musculoskeletal injury that impairs pedalling * Appearance of a multiple sclerosis attack in the 90 days preceding the study * Recent adjustment of any medication or drug that may have an impact on fatigue: treatment of neuropathic pain: anti-epileptic and/or taking stimulants for fatigue (e.g. modafinil, amantadine, fampridine...) * History of comorbid illness or conditions that would compromise the subject's safety during the study * Participation at the same time in another medical intervention study or having participated in such a study in the 30 days prior to this study * Pregnant and breast-feeding women * Patients who are unable to understand the purpose of the study and the conditions under which it will be conducted, or who are unable to give their consent. * Patients deprived of their liberty or under guardianship

Primary outcome measure(s)

  • Fatigue Severity Scale (FSS) — Week 15
    Change in the chronic fatigue score assessed using the FSS questionnaire before and after the training programme. From 1 to 7. The higher the score, the greater the fatigue

Trial sites (1)

FacilityCityRegionStatus
Chu de Saint-Etienne Saint-Etienne France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06201026 on ClinicalTrials.gov ↗ ← All trials in France